Collegium Pharmaceutical (COLL) Change in Receivables (2016 - 2026)

Collegium Pharmaceutical's Change in Receivables history runs 11 years deep, the most recent figure standing at $17.4 million for Q1 2026.

• On a quarterly basis, Change in Receivables rose 10155.29% year-over-year to $17.4 million in Q1 2026; TTM through Mar 2026 was $60000.0, a 99.36% decrease from a year earlier, with the FY2025 full-year figure at -$17.2 million, down 489.76% from the prior year.
• Change in Receivables advanced to $17.4 million in Q1 2026 per COLL's latest filing, from -$22.6 million in the prior quarter.
• Across five years, Change in Receivables topped out at $31.2 million in Q2 2022 and bottomed at -$22.6 million in Q4 2025.
• The 5-year median for Change in Receivables is -$106000.0 (2024), against an average of $1.3 million.
• Biggest YoY gain for Change in Receivables was 10913.68% in 2025; the steepest drop was 21240.57% in 2025.
• Year by year, Change in Receivables stood at -$12.3 million in 2022, then jumped by 81.06% to -$2.3 million in 2023, then soared by 95.44% to -$106000.0 in 2024, then slumped by 21240.57% to -$22.6 million in 2025, then jumped by 177.07% to $17.4 million in 2026.
• Per Business Quant, the three latest COLL Change in Receivables figures stand at $17.4 million (Q1 2026), -$22.6 million (Q4 2025), and $20.9 million (Q3 2025).